Mylan Australia Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Mylan Australia Pharmaceutical Import Records from India — 3 Products, $6.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Australia — Pharmaceutical Importer Profile (2026) | 3 Products, $6.3M Trade | TransData Nexus

Mylan Australia

Pharmaceutical Importer · Australia · Antibiotics Focus · $6.3M Total Trade · DGFT Verified

Mylan Australia is a pharmaceutical importer based in Australia with a total trade value of $6.3M across 3 products in 3 therapeutic categories. Based on 142 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Mylan Australia sources from 4 verified Indian suppliers, with Mylan Laboratories Limited accounting for 46.4% of imports.

Mylan Australia — Import Portfolio & Supplier Network

Mylan Australia import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylan Australia?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$9.0M	213	46.4%
Medreich Limited	$7.5M	262	38.8%
Cipla Limited	$2.8M

What Formulations Does Mylan Australia Import?

Formulation	Value	Ships
Vancomycin viatris foi 1g 1s mylan	$1.1M	22
Dexamethasone mylan INJ 8MG/2ML 5s myl	$852.8K	18
Amoxicillin capsules BP 500MG	$830.3K	18
Dymista (azelastine hydrochloride 137mcg+fluticasone propionate 50mcg (per spray) nasal suspension);dymista trade Pack	$613.1K	13
Dymista (azelastine hydrochloride 137mcg	$600.0K	12
Dexametha sod INJ USP 4MG/ML 1ML 25	$561.8K	12
Dymista azelastine hydrochloride 137mcg	$550.0K	11
Dymista azelastine hydrochloride 137mcg fluticasone propionate 50mcg per spray nasal suspension dymista trade	$400.0K	8
Clindamycin mylan 150MG/ML 4ML 10s pf	$350.0K	7
Dymista azelastine hydrochloride 137mcg+fluticasone propionate 50mcg per spray nasal suspension;dymista trade Pack	$350.0K	7
Vecure pwd foi 10MG 10s mylan aus	$300.0K	6
Flucloxacillin capsules 500MG	$300.0K	6
Dymista azelastine hydrochloride 137mcg fluticasone propionate 50mcg per spray nasal suspension dymista trade	$300.0K	6
Aciclovir viatris 250MG 5s australia	$250.0K	5
Dexamethasone viatris INJ	$250.0K	5

Mylan Australia imports 324 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Vancomycin	Antibiotics	$2.8M	55	3.0%	9
2	Dexamethasone	Corticosteroids	$1.9M	53	1.0%	14
3	Fluticasone	Respiratory	$1.7M	34	0.8%	6

Mylan Australia imports 3 pharmaceutical products across 3 categories into Australia totaling $6.3M.

Mylan Australia — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan Australia Pty Limited, established on 10 August 2007, is an Australian proprietary company specializing in the importation and distribution of pharmaceutical products. Headquartered in New South Wales, Australia, the company operates as a subsidiary of Viatris Inc., a global healthcare company formed in November 2020 through the merger of Mylan and Upjohn, Pfizer's off-patent medicine division. (viatris.com.au) Mylan Australia plays a significant role in the Australian pharmaceutical supply chain by sourcing and supplying a diverse range of generic and specialty medicines to meet the country's healthcare needs.

2Distribution Network

While specific details about Mylan Australia's warehouse locations and logistics capabilities are not publicly disclosed, the company is known to operate a research and manufacturing center in Carole Park, Queensland. This facility likely supports the distribution of pharmaceutical products across Australia. Given its affiliation with Viatris, Mylan Australia benefits from an extensive global distribution network, enabling efficient logistics and supply chain management to ensure timely delivery of medicines throughout the country.

3Industry Role

Mylan Australia functions primarily as a pharmaceutical importer and distributor within Australia's supply chain. The company sources finished pharmaceutical formulations from various international suppliers, including Indian manufacturers, and supplies these products to Australian healthcare providers, pharmacies, and hospitals. By importing a diverse range of generic and specialty medicines, Mylan Australia contributes to enhancing the accessibility and affordability of healthcare in Australia.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylan Australia

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mylan Australia's sourcing strategy exhibits a notable concentration on a select group of suppliers. The company's total import value from India amounts to $6.3 million USD, with 142 shipments covering 324 unique formulations. The top three suppliers are:

MYLAN LABORATORIES LIMITED: $9.0 million (46.4% of total imports)
MEDREICH LIMITED: $7.5 million (38.8% of total imports)
CIPLA LIMITED: $2.8 million (14.6% of total imports)

This concentration suggests a strategic choice to maintain strong, stable relationships with key suppliers, potentially ensuring consistent product quality and supply reliability. However, such dependency may also pose risks if any of these suppliers encounter operational challenges or regulatory issues.

2Supply Chain Resilience

Mylan Australia's supply chain resilience is bolstered by its partnerships with multiple suppliers, including MYLAN LABORATORIES LIMITED, MEDREICH LIMITED, and CIPLA LIMITED. The diversity in suppliers and the importation of 324 unique formulations indicate a strategic approach to mitigate risks associated with single-source dependency. While the company primarily sources from India, the reliance on a limited number of suppliers may expose it to potential disruptions. Ensuring that these suppliers adhere to Good Manufacturing Practice (GMP) standards and maintaining alternative sourcing options are crucial for sustaining supply chain stability.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the regulation of pharmaceutical imports is overseen by the Therapeutic Goods Administration (TGA), which ensures that all therapeutic goods meet the necessary standards for quality, safety, and efficacy. The TGA operates under the Therapeutic Goods Administration Act 1989, which outlines the requirements for the importation, manufacturing, and distribution of therapeutic goods in Australia. Additionally, the Office of Drug Control (ODC) regulates the importation of controlled substances, issuing licenses and permits as per international conventions. (odc.gov.au)

2Import Licensing & GMP

To import therapeutic goods into Australia, companies must comply with the TGA's regulations, which include ensuring that all imported medicines are entered in the Australian Register of Therapeutic Goods (ARTG) before importation. This process involves obtaining an ARTG entry, for which the importer acts as the sponsor responsible for the application and maintenance of the entry. (tga.gov.au) Furthermore, imported medicines must be manufactured in accordance with Good Manufacturing Practice (GMP) standards, as stipulated by the TGA, to ensure product quality and safety. (tga.gov.au)

3Quality & Labeling

Mylan Australia — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mylan Australia's product strategy focuses on importing medicines across three therapeutic categories: antibiotics, corticosteroids, and respiratory treatments. The top three imported products are:

Vancomycin: $2.8 million (43.5% of total imports)
Dexamethasone: $1.9 million (29.7% of total imports)
Fluticasone: $1.7 million (26.9% of total imports)

This focus aligns with the significant demand for these therapeutic areas in the Australian market, addressing critical healthcare needs. The substantial import values indicate a strategic emphasis on these categories to meet patient requirements effectively.

2Sourcing Profile

Mylan Australia's sourcing strategy is centered on importing finished pharmaceutical formulations from India, particularly from suppliers like MYLAN LABORATORIES LIMITED, MEDREICH LIMITED, and CIPLA LIMITED. This approach leverages India's robust pharmaceutical manufacturing capabilities and cost advantages. By focusing on finished products, Mylan Australia ensures that the medicines are ready for distribution, streamlining the supply chain and reducing lead times.

Seller's Guide — How to Become a Supplier to Mylan Australia

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Australian market by meeting Mylan Australia's quality standards and regulatory requirements. Gaps in Mylan Australia's current sourcing include potential diversification of suppliers and formulations. Indian exporters can capitalize on these opportunities by offering high-quality products, ensuring compliance with Australian regulations, and establishing reliable supply chains.

2Requirements & Qualifications

Indian exporters aiming to supply Mylan Australia must ensure that their products are manufactured in accordance with GMP standards recognized by the TGA. They must also obtain ARTG entries for their products and comply with Australian labeling and serialization requirements. Additionally, exporters should be prepared to navigate the import licensing process, including obtaining necessary permits for controlled substances if applicable.

3How to Approach

To build a relationship with Mylan Australia, Indian exporters should initiate contact to understand the company's specific product requirements and quality standards. Participating in relevant tenders and responding to requests for proposals can provide opportunities to showcase product offerings. Developing a comprehensive regulatory filing strategy, including obtaining ARTG entries and ensuring compliance with GMP and labeling requirements, is essential. Establishing clear communication channels and understanding the import licensing process will facilitate a smoother entry into the Australian market.

Frequently Asked Questions — Mylan Australia

What products does Mylan Australia import from India?

Mylan Australia imports 3 pharmaceutical products across 3 categories. Top imports: Vancomycin ($2.8M), Dexamethasone ($1.9M), Fluticasone ($1.7M).

Who supplies pharmaceuticals to Mylan Australia from India?

Mylan Australia sources from 4 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (46.4% of imports, $9.0M).

What is Mylan Australia's total pharmaceutical import value?

Mylan Australia's total pharmaceutical import value from India is $6.3M, based on 142 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylan Australia focus on?

Mylan Australia imports across 3 categories. The largest: Antibiotics (43.5%), Corticosteroids (29.7%), Respiratory (26.9%).

Get Full Mylan Australia Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.